OncoMatch/Clinical Trials/NCT06498154
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
Is NCT06498154 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (IHC 3+ or IHC 2+ and ISH positive)
HER2 positive ( HR negative HER2 IHC score of 3+, or 2+and ISH test positive)
Required: ESR1 negative (negative)
HR negative HER2 IHC score of 3+, or 2+and ISH test positive
Required: PR (PGR) negative (negative)
HR negative HER2 IHC score of 3+, or 2+and ISH test positive
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any medication in this study
Has used any medication in this study within 14 days prior to enrollment
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L; PLT ≥ 90 × 10^9/L; Hb ≥ 90 g/L
Kidney function
BUN and Cr ≤ 1.5 × ULN
Liver function
TBIL ≤ 2.5 × ULN; ALT and AST ≤ 2.5 × ULN
Cardiac function
LVEF ≥ 50%; QTcF < 470 ms (females)
LVEF ≥ 50%; 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females<470ms; blood routine: ANC ≥ 1.5 × 109/L# PLT≥90 × 109/L# Hb≥90 g/L#Blood biochemistry: TBIL ≤ 2.5 × ULN# ALT and AST ≤ 2.5 × ULN# BUN and Cr ≤ 1.5 × ULN#
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06498154 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 negative is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages